Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3Ovarian Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × rucaparib × Clear all
NCT01009190 2023-06-08

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

pharmaand GmbH

Phase 1 Completed
85 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡